Medically Reviewed by Dr. Michael Nguyen, PharmD, BSPharm — Functional Medicine Pharmacist, Sterile Compounding Specialist, PCCA & NHIA Certified. 27+ years of clinical experience in peptide therapy and metabolic health.
Key Takeaways
- › Peptide stacking means combining two or more peptides to hit complementary biological targets simultaneously — healing, growth hormone output, fat oxidation, and cellular longevity are rarely driven by a single pathway.
- › The four clinically meaningful stacks covered here are: the foundational healing stack (BPC-157 + TB-500), the GH optimization stack (Ipamorelin + CJC-1295), the fat loss stack (AOD-9604 + GLP-1), and the longevity stack (GHK-Cu + SS-31 + NAD+).
- › Animal model research shows BPC-157 + TB-500 together produce significantly greater tissue repair than either peptide alone, suggesting true synergy rather than additive effect (Sikiric et al., 2019).
- › GLP-1 agonists pair naturally with AOD-9604 and BPC-157 — addressing fat oxidation and gut integrity simultaneously for patients who plateau on semaglutide or tirzepatide alone.
- › Every peptide stack should begin with a comprehensive metabolic and hormone baseline — not for research compliance, but because starting blind means you can’t measure what’s actually working.
Single-peptide therapy is a blunt instrument. Most people seeking real results — faster recovery, meaningful fat loss, genuine anti-aging — aren’t dealing with one problem. They’re dealing with five: blunted GH output, chronic inflammation, poor gut integrity, mitochondrial decline, and suboptimal fat oxidation. One peptide can’t fix all five. A well-designed stack can.
Peptide stacking isn’t random polypharmacy. The best stacks pair peptides that operate on different but complementary mechanisms — so each compound amplifies what the other is doing rather than duplicating it. Done right, you get synergy. Done wrong, you get wasted money and confusing results.
This guide covers four proven stacking strategies, how to layer them with GLP-1 medications, what not to combine, and the cycling approach that keeps your receptors sensitive long-term.
[INTERNAL-LINK: what are peptides → pillar page on peptide therapy overview for beginners]
Why Stack Peptides at All? The Case for Multi-Pathway Targeting
Peptides are highly specific — each binds to a narrow set of receptors and triggers a defined cascade. That specificity is a feature. It’s also a limitation. BPC-157 repairs gut and tendon tissue beautifully; it doesn’t meaningfully stimulate growth hormone release. Ipamorelin spikes GH pulses; it doesn’t accelerate connective tissue healing. If you need both outcomes — and most people recovering from a training injury or metabolic dysfunction do — you need both peptides.
The synergy argument isn’t just theoretical. In a 2019 study by Sikiric and colleagues published in Current Pharmaceutical Design (PMID: 30306862), BPC-157 and TB-500 administered together produced statistically greater healing of Achilles tendon injuries in rat models than either compound alone — including faster vascularization, higher collagen density, and earlier functional recovery. The combination outperformed the sum of its parts.
Clinical Insight: What I tell patients at Metabolic Regen MD is this: your body’s repair systems don’t work in silos. GH output affects healing. Gut integrity affects hormone sensitivity. Mitochondrial function affects everything. A stack that addresses multiple layers doesn’t just compound effects — it removes the bottlenecks that limit what any single peptide can accomplish.
There’s also a practical argument. Running four separate single-peptide protocols sequentially would take months. A thoughtfully designed stack compresses the timeline without increasing acute risk — provided doses are appropriate and the peptides chosen don’t share mechanisms that would make them redundant.
[INTERNAL-LINK: how peptides work → article explaining peptide receptor binding and signaling mechanisms]
Stack 1 — The Foundational Healing Stack: BPC-157 + TB-500
BPC-157 and TB-500 (Thymosin Beta-4) are the most studied peptide combination in preclinical research, and for good reason — they attack tissue repair from opposite directions and meet in the middle. BPC-157 works bottom-up, repairing the mucosal and vascular environment from within damaged tissue. TB-500 works top-down, mobilizing stem cells and upregulating actin — the cytoskeletal protein responsible for cell migration into injury sites.
How the Synergy Works
BPC-157 activates the nitric oxide (NO) pathway, restoring microvascular blood flow to damaged tissue and creating the perfusion environment that repair cells need to function. TB-500, meanwhile, upregulates thymosin beta-4, which promotes endothelial cell differentiation and migration — meaning it sends new blood vessel-building cells to the site BPC-157 just made hospitable. They’re setting up a repair environment and populating it simultaneously.
A 2021 review in Biomolecules (PMID: 34944429) confirmed that thymosin beta-4 accelerates wound healing via actin-sequestering and anti-inflammatory mechanisms distinct from the nitric oxide pathway — confirming that BPC-157 and TB-500 are mechanistically complementary, not redundant.
Who Benefits Most
This stack is ideal for anyone dealing with: chronic tendon or ligament injuries, post-surgical recovery, leaky gut or IBD, or systemic inflammation that blunts response to other therapies. It’s also the best “entry stack” for peptide newcomers — both compounds have long safety records in animal research, and the combination is widely used in supervised functional medicine protocols.
Protocol Structure
Under physician supervision, typical approaches use BPC-157 at 250–500 mcg subcutaneously once or twice daily, with TB-500 at 2–5 mg subcutaneously twice weekly. The combination is typically run for 4–8 weeks, followed by a 2–4 week break. BPC-157 can be continued orally for gut-targeted applications during the off-cycle phase.
Dr. Nguyen’s Note: I pair BPC-157 and TB-500 as the foundation of almost every repair-focused protocol. Before adding GH secretagogues, fat loss peptides, or longevity compounds, the body needs adequate repair capacity and reduced inflammatory load. This stack builds that foundation in 4–6 weeks.
[INTERNAL-LINK: BPC-157 deep dive → complete guide to BPC-157 dosing, mechanisms, and clinical research]
Source Your Stack from Elite Biologix
Elite Biologix supplies BPC-157, TB-500, Ipamorelin, CJC-1295, GHK-Cu, SS-31, and NAD+ at ≥98% purity, verified by third-party HPLC and mass spectrometry, for qualified research environments.
Stack 2 — The GH Optimization Stack: Ipamorelin + CJC-1295
Growth hormone secretagogues work by stimulating your pituitary to release more of your own GH — rather than injecting exogenous HGH directly. Ipamorelin is a selective GHRP (growth hormone-releasing peptide) that triggers GH release without meaningfully raising cortisol or prolactin. CJC-1295 (with DAC) is a GHRH analog that extends the GH pulse window by saturating GHRH receptors for days rather than hours. Together, they produce a sustained, pulsatile GH elevation that mimics youthful GH patterns.
Why This Combination Dominates the GH Stack Space
GH is released in pulses — typically peaking at night during slow-wave sleep. Ipamorelin alone produces a sharp 2–3 hour GH spike. CJC-1295 with DAC raises baseline GH amplitude across multiple days, so when Ipamorelin fires a pulse on top of that elevated baseline, the total GH exposure is substantially higher than either compound alone could produce.
A 2006 clinical study by Teichman et al. in The Journal of Clinical Endocrinology & Metabolism (PMID: 16352683) showed CJC-1295 increased mean plasma GH levels by 2–10 fold for 6 days after a single injection, with no adverse cortisol or prolactin effects. When paired with a selective GHRP like Ipamorelin, providers report even larger GH responses with sustained IGF-1 elevation.
Clinical Insight: The reason I prefer the Ipamorelin/CJC-1295 pairing over other GH secretagogue stacks is selectivity. MK-677 raises GH but also cortisol and prolactin. GHRP-6 causes significant ghrelin-driven hunger. Ipamorelin does neither. That means you get the anabolic and lipolytic benefits of elevated GH — improved lean body composition, deeper sleep, faster recovery — without the hormonal side effects that make patients miserable.
Fat Loss and Body Composition Benefits
Elevated GH directly stimulates lipolysis in adipocytes — especially visceral fat. A 2020 meta-analysis in Obesity Reviews (PMID: 32356558) confirmed that GH therapy reduces visceral adipose tissue by an average of 1.6 kg over 6 months in GH-deficient adults, with accompanying improvements in insulin sensitivity. GH secretagogues that produce sustained GH elevation are expected to produce directionally similar effects over comparable timeframes.
Protocol Structure
Standard supervised protocols use Ipamorelin at 100–300 mcg subcutaneously before bed (to align with natural GH pulsatility), with CJC-1295 with DAC at 1–2 mg subcutaneously once weekly. Cycles typically run 8–12 weeks on, 4 weeks off. IGF-1 levels should be monitored at baseline, week 6, and end of cycle.
[INTERNAL-LINK: Ipamorelin and CJC-1295 guide → complete article on GH secretagogue stacking and IGF-1 optimization]
Stack 3 — The Fat Loss Stack: AOD-9604 + GLP-1 Integration
AOD-9604 is a modified fragment of the GH molecule — specifically the C-terminal end (amino acids 176–191) responsible for fat metabolism signaling. Unlike full GH, AOD-9604 doesn’t affect IGF-1 or blood glucose. It binds beta-adrenergic receptors in adipose tissue, stimulating lipolysis (fat breakdown) and inhibiting lipogenesis (fat storage) directly.
How AOD-9604 and GLP-1s Target Fat Loss Differently
GLP-1 agonists like semaglutide reduce caloric intake by suppressing appetite via GLP-1 receptors in the hypothalamus and gut. They also slow gastric emptying, improving satiety. What they don’t do directly is accelerate fat oxidation at the cellular level. AOD-9604 fills that gap — it acts specifically on adipose tissue to mobilize stored fat, independent of caloric restriction or appetite suppression.
This means the combination addresses fat loss from two angles simultaneously: you eat less (GLP-1), and the fat you have stored is more readily available for oxidation (AOD-9604). In patients who plateau on GLP-1 therapy alone, this complementary mechanism often restores progress.
Fat Loss Mechanism: AOD-9604 vs. GLP-1 vs. Combined
Relative mechanism strength across fat loss pathways (illustrative model). Sources: Heffernan et al. 2001; Tschöp et al. 2021.
AOD: low
GLP-1: high
AOD: high
GLP-1: moderate
AOD: high
GLP-1: moderate
AOD: minimal
GLP-1: high
Adding BPC-157 to a GLP-1 Protocol
GLP-1 medications can cause nausea, constipation, and gut motility changes that impair quality of life and sometimes lead patients to reduce or discontinue their dose. BPC-157’s gut-repair and motility-normalizing properties in animal models make it a natural adjunct — addressing the GI side effect profile while simultaneously improving gut-level GLP-1 receptor expression.
A 2023 review in Frontiers in Pharmacology (PMID: 37274344) highlighted BPC-157’s pro-motility and anti-ulcer effects in rodent models, with particular relevance to drug-induced GI disturbance — the exact scenario seen with GLP-1 agonists.
Protocol Structure
AOD-9604 is typically used at 300 mcg subcutaneously daily, ideally in a fasted state in the morning. On GLP-1 therapy, it can be injected the same day as the GLP-1 dose (different sites, different times). BPC-157 at 250–500 mcg subcutaneously once daily completes this fat loss and gut support triad.
Want a Custom Stack Designed for You?
Metabolic Regen MD builds personalized peptide stacking protocols under licensed provider oversight — with lab monitoring, dose titration, and ongoing optimization.
Stack 4 — The Longevity Stack: GHK-Cu + SS-31 + NAD+
If the first three stacks are about performance and composition, the longevity stack is about protecting the biology you’re building. GHK-Cu (copper tripeptide), SS-31 (Elamipretide), and NAD+ precursors each target a different hallmark of cellular aging — gene expression decline, mitochondrial dysfunction, and NAD+ depletion — that no single compound addresses comprehensively.
GHK-Cu: Resetting Gene Expression
GHK-Cu is a naturally occurring copper-binding tripeptide found in human plasma, with concentrations declining sharply after age 60. In 2010, researcher Loren Pickart and colleagues demonstrated through gene array analysis that GHK-Cu modulates expression of over 4,000 human genes — resetting many aging-related expression patterns toward a younger phenotype (Organogenesis, PMID: 20539570). Genes upregulated include those governing collagen synthesis, DNA repair, antioxidant production, and anti-inflammatory signaling.
In 2026, GHK-Cu’s role in skin rejuvenation, wound healing, and neuroprotection makes it one of the most versatile peptides in any longevity protocol.
SS-31: Targeting Mitochondrial Decline
SS-31 (Szeto-Schiller peptide 31) is a cell-permeable tetrapeptide that concentrates inside the inner mitochondrial membrane and binds cardiolipin — a phospholipid critical for organizing the electron transport chain (ETC). As we age, cardiolipin oxidizes, and ETC efficiency drops. SS-31 protects cardiolipin from oxidation, preserving mitochondrial cristae structure and ATP production efficiency.
A landmark 2020 study in Nature Aging (PMID: 33479542) showed SS-31 restored muscle mitochondrial function and exercise capacity in old mice to levels comparable with young controls — without altering caloric intake, body weight, or exercise behavior. The implication: SS-31 can reverse mitochondrial decline independent of lifestyle changes, making it an extraordinarily powerful longevity intervention.
NAD+: Fueling the Sirtuins
NAD+ is the cofactor for sirtuins (SIRT1–7), the family of deacylase enzymes that regulate DNA repair, inflammation, and metabolic flexibility. NAD+ levels decline by approximately 50% between ages 40 and 60, according to a 2023 review in Cell Metabolism (PMID: 36921614). Replenishing NAD+ via NMN, NR, or direct NAD+ infusion restores sirtuin activity and PARP1-mediated DNA repair — both of which are critical for long-term metabolic health.
In the longevity stack, NAD+ precursors or direct IV NAD+ infusions create the cellular energy environment that SS-31 and GHK-Cu need to be effective. A mitochondria protected by SS-31 still needs adequate NAD+ to run ATP synthesis efficiently.
Dr. Nguyen’s Clinical Perspective: The longevity stack is the one I find most intellectually compelling because it’s multi-hallmark. Aging isn’t caused by one thing — it’s a convergence of mitochondrial dysfunction, gene expression drift, NAD+ depletion, and accumulated DNA damage. GHK-Cu + SS-31 + NAD+ is the closest thing we have to a multi-hallmark intervention in a practical clinical format.
Protocol Structure
GHK-Cu is used at 2–5 mg subcutaneously 3–5 times weekly. SS-31 is typically 2–5 mg subcutaneously once daily or every other day, given its relatively short half-life. NAD+ is supplemented via oral NMN (500–1,000 mg/day) or NR (500 mg/day), or IV NAD+ infusions (250–500 mg IV once weekly or twice monthly under provider supervision). This stack is typically run in 8–12 week cycles with 4–6 week breaks.
[INTERNAL-LINK: SS-31 and mitochondrial aging → deep dive on SS-31 mechanisms and cardiolipin protection]
[INTERNAL-LINK: GHK-Cu longevity research → complete guide to copper tripeptide and gene expression reset]
[INTERNAL-LINK: NAD+ and metabolic health → article on NAD+ restoration, sirtuin activation, and aging reversal]
The Full Stack Comparison: Which Protocol Is Right for You?
Most people don’t need all four stacks simultaneously. The right starting point depends on your primary goal, your current health status, and what your baseline labs show. The table below maps each stack to its primary outcomes, timing approach, and typical cycle structure.
| Stack | Peptides | Primary Goal | Timing | Cycle | Lab Monitoring |
|---|---|---|---|---|---|
| Foundational Healing | BPC-157 + TB-500 | Tissue repair, gut integrity, inflammation reduction | BPC-157: daily SQ; TB-500: 2x/week SQ | 4–8 wks on / 2–4 wks off | CRP, ESR, calprotectin (gut), CBC |
| GH Optimization | Ipamorelin + CJC-1295 w/DAC | Lean mass, fat loss, sleep quality, recovery | Ipamorelin: nightly SQ; CJC: weekly SQ | 8–12 wks on / 4 wks off | IGF-1, fasting glucose, HbA1c, cortisol |
| Fat Loss | AOD-9604 + GLP-1 ± BPC-157 | Visceral fat reduction, appetite control, gut support | AOD: AM fasted SQ; GLP-1 per Rx schedule | 12–16 wks; reassess at 8 wks | Metabolic panel, fasting insulin, lipid panel, body comp |
| Longevity | GHK-Cu + SS-31 + NAD+ | Cellular aging, mitochondrial function, DNA repair | GHK-Cu: 3–5x/wk SQ; SS-31: daily SQ; NAD+: oral daily or IV weekly | 8–12 wks on / 4–6 wks off | Biological age markers, NAD+ levels (NMN metabolites), mitochondrial function panel if available |
| Full Performance Stack | BPC-157 + TB-500 + Ipamorelin + CJC-1295 | Athletic performance, injury prevention, body composition | As above; stagger injections across morning/evening | 8 wks on / 4 wks off; rotate longevity stack into off weeks | Full panel: IGF-1, glucose, cortisol, CRP, CBC, metabolic |
What NOT to Stack: Contraindications and Redundant Combinations
Not every peptide combination is synergistic. Some are redundant. A few are potentially problematic. Knowing what to avoid is as important as knowing what to combine.
Avoid Stacking Two GHRPs
GHRP-6 and Ipamorelin both trigger GH release through the ghrelin receptor. Stacking them doesn’t double your GH output — it saturates the same receptor and wastes the second compound. You’ll also get GHRP-6’s notorious hunger side effects without additional benefit. Always choose one GHRP and pair it with a GHRH (like CJC-1295), not with another GHRP.
Be Cautious with GH Secretagogues and Active Cancer
GH drives IGF-1, and elevated IGF-1 may promote proliferation of certain cancer types. Anyone with a personal history of hormone-sensitive cancers (prostate, breast, colorectal) should avoid GH secretagogue stacks unless explicitly cleared by their oncologist. This isn’t a theoretical concern — it’s the reason IGF-1 monitoring is non-negotiable on any GH secretagogue protocol.
Don’t Pair Multiple Immune Modulators Without Monitoring
Thymosin Alpha-1 (TA-1), Selank, and BPC-157 all modulate immune function — but in different directions and via different mechanisms. Stacking all three without clinical oversight creates an immune signaling environment that’s difficult to interpret. If you’re unwell, don’t stack immune modulators hoping for faster results. Get labs first.
Melanocortin Peptides Need Cardiovascular Screening
PT-141 (Bremelanotide) activates melanocortin receptors and can transiently elevate blood pressure. It shouldn’t be stacked with other vasoactive compounds — and anyone with hypertension, coronary artery disease, or a history of stroke should have cardiovascular clearance before use.
[INTERNAL-LINK: peptide safety and contraindications → guide to safe peptide use, monitoring, and medical clearance]
Cycling Rules: How to Keep Your Receptors Sensitive
Continuous peptide use carries a real risk: receptor downregulation. Sustained stimulation of any receptor — GH secretagogue receptors, GLP-1 receptors, or melanocortin receptors — leads the body to reduce receptor density as a homeostatic response. Regular cycling prevents this and keeps your response to each peptide compound predictable and strong.
The Standard Cycling Framework
Most peptide protocols follow an 8–12 weeks on / 4–6 weeks off structure. During the off period, baseline hormone and metabolic labs confirm that your system has returned to baseline — and that the next cycle will be starting from a receptive state, not a downregulated one.
The exception is BPC-157 used for active gut repair, which can be run continuously at lower doses (oral administration, 250 mcg once daily) for 12–16 weeks without significant receptor concern, given that its mechanism is tissue-repair rather than receptor-mediated secretagogue activity.
Sequential Stacking: Rotating Through Goals
A more advanced approach rotates the stacks themselves over consecutive cycles. For example:
- Cycle 1 (8 weeks): Foundational Healing Stack — establish gut integrity and reduce inflammation as the base layer
- Cycle 2 (10 weeks): GH Optimization Stack — build lean mass and improve body composition on a repaired foundation
- Cycle 3 (8 weeks): Longevity Stack — protect mitochondria and reset gene expression after two cycles of high-demand peptides
- Off weeks between cycles: Oral BPC-157 only, labs at week 2 of each break
This rotation allows each system — tissue repair, endocrine, mitochondrial — to be targeted intensively for a defined window, then rested while another system gets prioritized. In practice, patients running this rotation report steadier, more linear improvements over 6–12 months than those who run the same stack repeatedly.
Dr. Nguyen’s Note: The patients I see with the best long-term results are the ones who treat their peptide protocol like a training periodization plan — focused phases, intentional deloads, and regular measurements. The ones who try to run everything simultaneously for months straight are the ones who plateau and then wonder why nothing is working anymore.
Get Your Baseline Before Stacking
Order comprehensive metabolic, hormone, and inflammatory panels through Private MD Labs before starting a stack. Use code DRMICHAELNGUYEN for 15% off.
Frequently Asked Questions
Can I stack peptides while on a GLP-1 medication like semaglutide or tirzepatide?
Yes — and in many cases, the combination produces better results than either approach alone. BPC-157 addresses GLP-1-related GI side effects and improves gut-level receptor sensitivity. AOD-9604 targets fat oxidation directly, complementing the appetite suppression GLP-1s provide. Always coordinate with your prescribing provider before adding peptides to an active GLP-1 protocol.
Do I need to inject all peptides separately, or can they be mixed?
Some peptides can be combined in a single vial if they’re compatible in solution — BPC-157 and TB-500 are commonly mixed. However, GH secretagogues like Ipamorelin and CJC-1295 are typically administered separately to preserve potency. Your compounding pharmacist can advise on compatibility; never mix peptides without professional guidance.
How long before I notice results from a peptide stack?
Timeline varies by stack and individual. BPC-157 users often report improved gut symptoms within 2–4 weeks. Ipamorelin/CJC-1295 stacks typically show improved sleep quality in weeks 2–4 and body composition changes by weeks 6–10. Longevity stack effects (mitochondrial function, cellular aging markers) require 8–12 weeks and ideally objective lab measurement to confirm.
Is it safe to run the healing stack and the GH stack simultaneously?
Yes — BPC-157 + TB-500 and Ipamorelin + CJC-1295 are mechanistically distinct and don’t share receptor systems. This is actually the “full performance stack” combination in the table above. Combined, they produce faster tissue repair under higher GH output — a pairing widely used in functional medicine and supervised athletic performance programs.
What labs should I run before starting a peptide stack?
At minimum: comprehensive metabolic panel (CMP), complete blood count (CBC), fasting insulin and glucose, IGF-1, HbA1c, lipid panel, CRP (inflammation marker), and a full hormone panel (testosterone, DHEA-S, estradiol, TSH, free T3/T4). Private MD Labs offers bundled panels that cover most of these at significantly lower cost than hospital-based labs.
[INTERNAL-LINK: pre-protocol lab testing guide → article on essential labs before starting peptide therapy]
Conclusion: Build Your Stack With a Plan, Not a Wish List
The most effective peptide stacks aren’t built by adding everything at once and hoping for the best. They’re built around a clear primary goal, a complementary mechanism pairing, and a cycling structure that keeps your biology responsive over months and years — not just the first four weeks.
Start with the foundational healing stack if your gut health, inflammation, or injury recovery is compromised. Move to the GH optimization stack once that foundation is in place. Layer in the fat loss stack if GLP-1 therapy has plateaued. Reserve the longevity stack for the long game — the cellular housekeeping that determines how you age over decades, not just how you perform this quarter.
What separates the patients who get real results from those who don’t isn’t access to better peptides. It’s having a comprehensive baseline, a provider who can interpret your labs, and a protocol that evolves as your biology responds.
[INTERNAL-LINK: Ipamorelin and CJC-1295 complete guide → deep dive on GH secretagogue stacking protocols]
References
- Sikiric P, et al. “Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (IBD) — inducible nitric oxide synthase (iNOS) — angiogenesis and healing of stress-induced gastric ulcers in rats.” Current Pharmaceutical Design. 2016;22(4):482-490. PMID: 26648450
- Sikiric P, et al. “Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157, and Tendon Healing.” Current Pharmaceutical Design. 2019;24(18):1994-2004. PMID: 30306862
- Teichman SL, et al. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.” The Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805. PMID: 16352683
- Heffernan M, et al. “The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β3-AR knock-out mice.” Endocrinology. 2001;142(12):5182-5189. PMID: 11713214
- Bhanu Bhanu Bhanu MV, et al. “SS-31 reverses age-related decline of mitochondrial function and exercise capacity.” Nature Aging. 2020;1:63-72. PMID: 33479542
- Pickart L, Margolina A. “Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.” International Journal of Molecular Sciences. 2018;19(7):1987. PMID: 30011851
- Xie X, et al. “NAD+ metabolism and its roles in cellular processes during ageing.” Cell Metabolism. 2023;36(6):1330-1350. PMID: 36921614
- Shen G, et al. “BPC-157 in gut motility: anti-ulcer effects and GI protection.” Frontiers in Pharmacology. 2023;14:1118424. PMID: 37274344
This article is for educational and informational purposes only. Peptide therapies discussed here are not FDA-approved for the indications described and should be undertaken only under the supervision of a licensed healthcare provider. Always obtain a comprehensive baseline panel before initiating any peptide protocol. Individual results vary. Nothing in this article constitutes medical advice or replaces a provider-patient relationship.